| Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system S Letendre, J Marquie-Beck, E Capparelli, B Best, D Clifford, AC Collier, ... Archives of neurology 65 (1), 65-70, 2008 | 1005 | 2008 |
| Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy TA Glauser, A Cnaan, S Shinnar, DG Hirtz, D Dlugos, D Masur, PO Clark, ... New England Journal of Medicine 362 (9), 790-799, 2010 | 697 | 2010 |
| Intravenous gamma-globulin treatment and retreatment in Kawasaki disease JC Burns, EV Capparelli, JA Brown, JW Newburger, MP Glode, ... The Pediatric infectious disease journal 17 (12), 1144-1148, 1998 | 521 | 1998 |
| Effect of HIV antibody VRC01 on viral rebound after treatment interruption KJ Bar, MC Sneller, LJ Harrison, JS Justement, ET Overton, ME Petrone, ... New England Journal of Medicine 375 (21), 2037-2050, 2016 | 469 | 2016 |
| Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection RM Lynch, E Boritz, EE Coates, A DeZure, P Madden, P Costner, ... Science translational medicine 7 (319), 319ra206-319ra206, 2015 | 459 | 2015 |
| Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study RK Heaton, DR Franklin Jr, R Deutsch, S Letendre, RJ Ellis, K Casaletto, ... Clinical Infectious Diseases 60 (3), 473-480, 2015 | 434 | 2015 |
| Summary proceedings from the neonatal pain-control group KJS Anand, JV Aranda, CB Berde, SA Buckman, EV Capparelli, W Carlo, ... Pediatrics 117 (Supplement_1), S9-S22, 2006 | 374 | 2006 |
| Infliximab treatment of intravenous immunoglobulin–resistant Kawasaki disease JC Burns, BM Best, A Mejias, L Mahony, DE Fixler, HS Jafri, ME Melish, ... The Journal of pediatrics 153 (6), 833-838. e6, 2008 | 336 | 2008 |
| Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation MA Brodsky, BJ Allen, EV Capparelli, CR Luckett, R Morton, WL Henry The American journal of cardiology 63 (15), 1065-1068, 1989 | 283 | 1989 |
| Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults Clinical & Experimental Immunology 182 (3), 289-301, 2015 | 273 | 2015 |
| Improved vancomycin dosing in children using area under the curve exposure J Le, JS Bradley, W Murray, GL Romanowski, TT Tran, N Nguyen, S Cho, ... The Pediatric infectious disease journal 32 (4), e155-e163, 2013 | 253 | 2013 |
| Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources RJ Ellis, AC Gamst, E Capparelli, SA Spector, K Hsia, T Wolfson, ... Neurology 54 (4), 927-936, 2000 | 237 | 2000 |
| Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure LP James, L Letzig, PM Simpson, E Capparelli, DW Roberts, JA Hinson, ... Drug Metabolism and Disposition 37 (8), 1779-1784, 2009 | 221 | 2009 |
| Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults MR Gaudinski, EE Coates, KV Houser, GL Chen, G Yamshchikov, ... PLoS medicine 15 (1), e1002493, 2018 | 209 | 2018 |
| Reduced lopinavir exposure during pregnancy AM Stek, M Mirochnick, E Capparelli, BM Best, C Hu, SK Burchett, C Elgie, ... Aids 20 (15), 1931-1939, 2006 | 206 | 2006 |
| Model appropriateness and population pharmacokinetic modeling EI Ette, PJ Williams, YH Kim, JR Lane, MJ Liu, EV Capparelli The Journal of Clinical Pharmacology 43 (6), 610-623, 2003 | 204 | 2003 |
| Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis MJ Abzug, G Cloud, J Bradley, PJ Sánchez, J Romero, D Powell, ... The Pediatric infectious disease journal 22 (4), 335-340, 2003 | 178 | 2003 |
| Pharmacokinetics of antiretrovirals in pregnant women M Mirochnick, E Capparelli Clinical pharmacokinetics 43, 1071-1087, 2004 | 166 | 2004 |
| Low atazanavir concentrations in cerebrospinal fluid BM Best, SL Letendre, E Brigid, DB Clifford, AC Collier, BB Gelman, ... Aids 23 (1), 83-87, 2009 | 150 | 2009 |
| Phase I clinical trial results of auranofin, a novel antiparasitic agent EV Capparelli, R Bricker-Ford, MJ Rogers, JH McKerrow, SL Reed Antimicrobial agents and chemotherapy 61 (1), 10.1128/aac. 01947-16, 2017 | 139 | 2017 |
